MF,PMF,PPV-MF,PET-MF
Conditions
Brief summary
This trial adopts a multicenter, open-label, positive drug parallel control clinical trial design, planning to enroll approximately 75 MF participants. Eligible participants will be stratified and assigned in a 1:1:1 ratio to the low-dose flonoltinib maleate tablet group, high-dose flonoltinib maleate tablet group, or the ruxolitinib tablet group. Stratification factor include the Dynamic International Prognostic Scoring System (DIPSS) risk classification (intermediate-2 and high risk)
Interventions
DRUGFlonoltinib 50mg
Flonoltinib 50mg, QD
Flonoltinib 100mg, QD
DRUGRuxolitinib
For patients with platelet counts between 100×10\^9/L and 200×10\^9/L, the recommended starting dose is 15 mg twice daily (bid). For patients with platelet counts \>200×10\^9/L, the recommended starting dose is 20 mg bid. For patients with platelet counts between 50×10\^9/L and \<100×10\^9/L, the recommended maximum starting dose is 5 mg bid.
Sponsors
Chengdu Zenitar Biomedical Technology Co., Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years, no gender restrictions; 2. Diagnosed with primary myelofibrosis (PMF) according to WHO criteria (2016 edition) or post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET-MF) according to IWG-MRT criteria; 3. Evaluated as intermediate-2 or high-risk myelofibrosis according to the Dynamic International Prognostic Scoring System (DIPSS) risk classification; 4. Expected survival ≥ 24 weeks; 5. ECOG score of 0-2; 6. Splenomegaly: palpable spleen edge reaching or exceeding 5 cm below the costal margin (distance from the intersection of the left midclavicular line and the left costal margin to the farthest point of the spleen); or not palpable due to body habitus (obesity) but confirmed by magnetic resonance imaging (MRI ) (or CT scan if necessary) at screening with spleen volume ≥ 450 cm³; 7. Blasts in peripheral blood and bone marrow ≤ 10%; 8) Within 7 days before the first dose, absolute absolute neutrophil count (ANC )≥ 1.0×10\^9/L, platelet count ≥ 50×10\^9/L, hemoglobin (HGB )\> 60 g/L (participants should not have received growth factors, colony-stimulating factors, thrombopoietic agents, or platelet transfusions within 2 weeks before the baseline assessment prior to the first dose); 9) Major organ function basically normal within 7 days before the first dose; 10) Able to understand and voluntarily sign the informed consent form.
Exclusion criteria
1. Previous anticancer treatment-related toxic reactions have not recovered to grade 1 or below (excluding alopecia and conditions specified in inclusion criteria 8 and 9), or have not fully recovered from previous surgery (major surgery within 4 weeks); 2. Hypersensitivity, allergic to the investigational drug or its excipients; 3. Previous intolerance or resistance to ruxolitinib; 4. Use of JAK inhibitors within 4 weeks before the first dose; 5. Any significant clinical and laboratory abnormalities that, in the investigator's opinion, affect safety evaluation; 6. History of congestive heart failure, unstable angina, myocardial infarction, cerebrovascular accident (excluding lacunar infarction), or pulmonary embolism within 6 months prior to screening; 7. Impaired cardiac function or arrhythmic disease requiring treatment at screening; 8. Any active infection requiring intravenous antibiotic treatment at screening; 9. Active tuberculosis infection within 48 weeks prior to screening or latent tuberculosis infection indicated by tuberculosis-related tests during the screening period; 10. Patients who have undergone splenectomy or received radiation therapy to the spleen area within 12 months before the first dose; 11. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, except for: a) HBV infection: Patients with positive hepatitis B surface antigen (HbsAg) or hepatitis B core antibody (HbcAb) with undetectable peripheral blood HBV-DNA (below the detection limit of the testing laboratory) can be enrolled; they must continue antiviral therapy and have HBV-DNA testing every 12 weeks and at the end of treatment (EOT); b) HCV seropositive patients with negative HCV RNA can be enrolled. 12. Positive for human immunodeficiency virus antibody (HIV-Ab) or Treponema pallidum antibody (TP-Ab) (patients with positive Treponema pallidum antibody can have a titer test, and the investigator will determine eligibility based on comprehensive judgment); 13. Patients with epilepsy or those using psychiatric drugs or sedatives at screening (excluding those used for sleep purposes); 14. Pregnant or breastfeeding women, and patients with reproductive potential (male and female) who refuse to use contraceptive measures during the trial and for 6 months after the trial; 15. Patients who have had another malignancy within 5 years before the first dose (excluding cured in-situ carcinoma and basal cell carcinoma of the skin); 16. Patients with other severe diseases that, in the investigator's opinion, may affect safety or compliance; 17. Patients who participated in other clinical trials of investigational drugs or medical devices within 1 month before the first dose and used the investigational drug or device; 18. Use of any treatment for MF (other than JAK inhibitors) within 2 weeks or 5 half-lives (whichever is longer) before the first dose, any immunomodulatory agents (e.g., thalidomide), any immunosuppressants, ≥10 mg/day prednisone or equivalent biological potency corticosteroids, or growth factors (e.g., erythropoietin (EPO)) (Traditional Chinese medicine should be stopped 1 day before the first dose); 19. Patients with a history of congenital or acquired bleeding disorders; 20. Other factors that the investigator deems unsuitable for participation in the trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of subjects with ≥35% reduction in spleen volume from baseline(Evaluation by IRC) | Week 24 | Percentage of subjects with ≥35% reduction in spleen volume from baseline(Evaluation by IRC) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of subjects with ≥35% reduction in spleen volume from baseline (Evaluation by researcher) | Week 24 | Percentage of subjects with ≥35% reduction in spleen volume from baseline(Evaluation by researcher) |
| Percentage of subjects with ≥35% reduction in spleen volume from baseline (Evaluation by IRC) | Week 12 | Percentage of subjects with ≥35% reduction in spleen volume from baseline( Evaluation by IRC) |
| Percentage of subjects with ≥50% reduction in MPN-SAF TSS scale total symptom score | Week 24 and Week 12 | Percentage of subjects with ≥50% reduction in MPN-SAF TSS scale total symptom score |
| Objective response rate (ORR = CR + PR) per the IWG-MRT consensus criteria. | Week 24 | Objective response rate (ORR = CR + PR) per the IWG-MRT consensus criteria. |
Countries
China
Contacts
Primary ContactLiangkun Sun
Backup ContactZheng Jiang
Outcome results
None listed